阅读说明：本技术 抗螺杆菌药剂及其使用方法 (Anti-helicobacter agents and methods of use thereof ) 是由 I·Y·奇切林 于 2019-04-24 设计创作，主要内容包括：本组发明涉及医学领域,并且可以在患有由幽门螺杆菌(Helicobacter pylori,H.pylori)引起的胃炎以及胃和十二指肠溃疡疾病的患者中用作药物。该组发明的技术结果是消除了用于实现高抗螺杆菌活性的治疗剂对身体的毒性作用。该抗螺杆菌药剂的技术结果是这样实现的,即所述抗螺杆菌药剂是有效治疗剂量的组合物,所述组合物由以低聚果糖和菊糖形式的益生元组分以及以乳酸钙形式的代谢组分组成,所述有效治疗剂量确保胃粘膜的定植抗力和幽门螺杆菌的根除。该方法的技术效果是这样实现的,即抗螺杆菌药剂的使用方法包括以有效治疗剂量口服给药根据权利要求1-5所述的抗螺杆菌药剂。(The present invention relates to the field of medicine and can be used as a medicament in patients suffering from gastritis caused by Helicobacter pylori (h. pylori) and gastric and duodenal ulcer diseases. The technical result of this group of inventions is the elimination of the toxic effects on the body of the therapeutic agents used to achieve high anti-helicobacter activity. The technical result of the anti-helicobacter agent is achieved in that said agent is a therapeutically effective amount of a composition consisting of a prebiotic component in the form of fructo-oligosaccharides and inulin and a metabolic component in the form of calcium lactate, said therapeutically effective amount ensuring colonization resistance of the gastric mucosa and eradication of helicobacter pylori. The technical result of the method is achieved in that the method of using the anti-helicobacter agent comprises orally administering a therapeutically effective amount of the anti-helicobacter agent according to claims 1 to 5.)

1. An anti-Helicobacter agent, wherein said agent is a therapeutically effective amount of a composition comprising a prebiotic component in the form of fructo-oligosaccharides and inulin and a metabolic component in the form of calcium lactate, said therapeutically effective amount providing resistance to colonization of the gastric mucosa and eradication of Helicobacter pylori (Helicobacter pylori).

2. An anti-helicobacter agent as claimed in claim 1 wherein said agent comprises 40 to 60% fructooligosaccharides, 20 to 30% inulin and 15 to 30% calcium lactate.

3. An anti-helicobacter agent as claimed in claim 1 wherein said agent comprises 55.1% fructooligosaccharide, 23.7% inulin and 21.2% calcium lactate.

4. The anti-helicobacter agent as claimed in claim 1, wherein said agent is in the form of a tablet of 0.5 to 1.0g per tablet.

5. The anti-helicobacter agent as claimed in claim 1, wherein said anti-agent is in the form of a powder.

6. The anti-helicobacter agent as claimed in claim 1, wherein said agent is in the form of a solution.

7. The anti-helicobacter agent as claimed in claim 1, wherein the therapeutically effective dose for adults and children aged 14 years and older is 3.0 to 4.5 g/day.

8. The anti-helicobacter agent as claimed in claim 1, wherein the therapeutically effective dose is 1.0 to 1.5 g/day for children aged 1 to 3 years and 1.5 to 3.0 g/day for children aged 3 to 14 years.

9. The anti-helicobacter agent as claimed in claim 1, wherein the therapeutically effective dose to an animal is 10 to 20 mg/day, and said animal is a laboratory mouse.

10. The method of use of an anti-helicobacter agent as claimed in claims 1 to 9 wherein said agent is administered orally at said therapeutically effective dose from 1 to 3 times per day.

11. The method of use of an anti-helicobacter agent as claimed in claim 10 wherein said agent is administered for the treatment of a condition caused by helicobacter pylori.

12. The method of use of an anti-helicobacter agent as claimed in claim 10, wherein said anti-helicobacter agent is administered for the treatment and prevention of gastric and duodenal ulcers caused by helicobacter pylori.

13. The method of use of an anti-helicobacter agent as claimed in claim 10 wherein said anti-helicobacter agent is administered for the treatment and prevention of gastritis caused by helicobacter pylori.

14. The method of use of an anti-helicobacter agent as claimed in claim 10, wherein said anti-helicobacter agent is administered for the treatment and prevention of an experimental disease (experimental disease) caused by helicobacter pylori.